Puma Biotechnology, Inc. Stock News

Puma SE is poised for a turnaround with strong growth plans in the US market and strategic athlete endorsements, leading me to assign a "Buy" recommendation. Despite recent subpar financial performance, Puma's robust dividend growth history and stable payout ratio indicate a solid foundation for future shareholder returns. My DCF analysis reveals that Puma is undervalued, with an intrinsic valu...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will present clinical data on its drug neratinib in a poster presentation on April 28 at the 2025 AACR Annual Meeting.

Puma SE's stock has dropped nearly 50% year-to-date, with an additional 20% decline following its Q4 earnings, creating a potential value opportunity for long-term investors. Despite consistent revenue growth, Puma has struggled with profitability as rising operating expenses have outpaced sales, leading to stagnant net income over the past several years. High-profile collaborations with cultur...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma's 2017 Employment Inducement Ince...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:00 p.m. ET on Tuesday, March 11, at Barclays 27th Annual Global Healthcare Conference. The conference will be held at the Loews Miami Beach. A live webcast of the prese...

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will provide an overview of Puma Biotechnology at the Barclays Annual Global Healthcare Conference at 2:00 p.m. ET on March 11.

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-Investor Relations Alan Auerbach – President and Chief Executive Officer Jeff Ludwig – Chief Commercial Officer Maximo Nougues – Chief Financial Officer Conference Call Participants Ed White – H.C. Wainwright Marc Frahm – TD Cowen Operato...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 4Q and FY-2024 earnings results after the close on Feb. 27 and follow with a conference call to discuss results.